Bacteria naturally present in the human intestine can transform cholesterol-derived bile acids into powerful metabolites that strengthen anticancer immunity by blocking androgen signaling, according to a preclinical study.
The newest episode of the Startup Cornell podcast features Jamey Edwards '96 MBA '03, president & chief strategy officer at Koko Home, a company providing radar driven, AI-enabled solutions for healthcare and an Entrepreneur in Residence of StartUp Health, which was founded in 2011 to invest in global health entrepreneurs.
Working toward more effective tuberculosis vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with “kill switches” that can be triggered to stop the bacteria after they activate an immune response.
An FDA-approved drug used in humans has been found to inhibit the growth of oral squamous cell carcinomas in dogs - with one dog’s tumor nearly disappearing in a matter of weeks.
Health information technology systems promised increased efficiency and reduced costs, but new ILR School-led research suggests these benefits have been elusive.
Hospices are increasingly owned by private equity firms and publicly traded companies, but recently Weill Cornell Medicine researchers found that they performed substantially worse than hospices owned by not-for-profit agencies.
A group of 34 earned their short white coats as the newest class in Weill Cornell Medicine’s Master of Science in Health Sciences for Physician Assistants program.